Earlier this year BrainStorm Cell Therapeutics Inc. announced that their Phase I/II clinical trial to test the tolerability and safety of their ALS treatment was fast tracked to a Phase IIa dose-escalating trial by the Israeli Ministry of Health. BrainStorm presented the results from their Phase I/II clinical trial at the 65th Annual Meeting of the American Academy of Neurology (AAN)Conference held this week in San Diego, California. BrainStorm plans to begin a Phase II trial in the United States later in 2013. This month it was announced that the Mayo Clinic would be the third clinical trial site, joining the University of Massachusetts and Massachusetts General Hospital (MGH).
Click here to read more.Share this: